A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- 16 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 07 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
- 12 Dec 2015 Interim results presented at the 38th Annual San Antonio Breast Cancer Symposium